High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1241-1249

  Müller Tidow, Carsten ^a   Schwäble, Joachim ^a   Steffen, Björn ^a   Tidow, Nicola ^a   Brandt, Burkhardt ^a   Becker, Kerstin ^a   Schulze Bahr, Eric ^a   Halfter, Hartmut ^a   Vogt, Ulf ^c   Metzger, Ralf ^b   Schneider, Paul M ^b   Büchner, Thomas ^a   Brandts, Christian ^a   Berdel, Wolfgang E ^a   Serve, Hubert ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c European Laboratory Association   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; EPHRIN RECEPTOR B6; FLT3 LIGAND; LEUKOCYTE TYROSINE KINASE; PROTEIN PTK7; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; BONE MARROW CELL; BRAIN TUMOR; CONTROLLED STUDY; DRUG TARGETING; GENE CLUSTER; GENE EXPRESSION; GENE OVEREXPRESSION; GENOME; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TESTIS CANCER;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; DNA PRIMERS; DNA, COMPLEMENTARY; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; HUMANS; MEMBRANE PROTEINS; MUTATION; NEOPLASMS; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TIME FACTORS; UP-REGULATION;

EID: 12144289595     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0954-03     Document Type: Article

References (35)

1. Robinson, D. R., Wu, Y. M., and Lin, S. F. The protein tyrosine kinase family of the human genome. Oncogene, 19: 5548-5557, 2000.
2. Hubbard, S. R., and Till, J. H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem., 69: 373-398, 2000.
3. Hunter, T. Signaling: 2000 and beyond. Cell, 100: 113-127, 2000.
4. Shawver, L. K., Slamon, D., and Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell, 1: 117-123, 2002.
5. Prenzel, N., Zwick, E., Leserer, M., and Ullrich, A. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res., 2: 184-190, 2000.
6. Brabender, J., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J., Salonga, D., Holscher, A. H., and Danenberg, P. V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res., 7: 1850-1855, 2001.
7. Tidow, N., Boecker, A., Schmidt, H., Agelopoulos, K., Boecker, W., Buerger, H., and Brandt, B. Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development. Cancer Res., 63: 1172-1178, 2003.
8. Stern, D. F. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res., 2: 176-183, 2000.
9. Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P. T., and Salgia, R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev., 13: 41-59, 2002.
10. Zinner, R. G., Kim, J., and Herbst, R. S. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer, 37: 17-27, 2002.
11. Levitzki, A. Tyrosine kinases as targets for cancer therapy. Eur. J. Cancer, 38 (Suppl. 5): S11-S18, 2002.
12. Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., Fretz, H., Zimmermann, J., Meyer, T., Caravatti, G., Furet, P., and Manley, P. W. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther., 93: 79-98, 2002.
13. Judson, I. Gastrointestinal stromal tumours (GIST): biology and treatment. Ann. Oncol., 13 (Suppl. 4): 287-289, 2002.
14. Müller-Tidow, C., Metzger, R., Kugler, K., Diederichs, S., Idos, G., Thomas, M., Dockhorn-Dworniczak, B., Schneider, P. M., Koeffler, H. P., Berdel, W. E., and Serve, H. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res., 61: 647-653, 2001.
15. ARF tumor suppressor in acute myeloid leukemia. Nat. Med., 8: 743-750, 2002.
16. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. Real time quantitative PCR. Genome Res., 6: 986-994, 1996.
17. Gibson, U. E., Heid, C. A., and Williams, P. M. A novel method for real time quantitative RT-PCR. Genome Res., 6: 995-1001, 1996.
18. Sawyers, C. L. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell, 1: 413-415, 2002.
19. Gilliland, D. G., and Griffin, J. D. The roles of FLT3 in hematopoiesis and leukemia. Blood, 100: 1532-1542, 2002.
20. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Loffler, H., Sauerland, C. M., Serve, H., Buchner, T., Haferlach, T., and Hiddemann, W. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100: 59-66, 2002.
21. Boissel, N., Cayuela, J. M., Preudhomme, C., Thomas, X., Grardel, N., Fund, X., Tigaud, I., Raffoux, E., Rousselot, P., Sigaux, F., Degos, L., Castaigne, S., Fenaux, P., and Dombret, H. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia (Baltimore), 16: 1699-1704, 2002.
22. 6-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin. Cancer Res., 9: 223-227, 2003.
23. Salonga, D. S., Danenberg, K. D., Grem, J., Park, J. M., and Danenberg, P. V. Relative gene expression in normal and tumor tissue by quantitative RT-PCR. Methods Mol. Biol., 191: 83-98, 2002.
24. Kindler, T., Breitenbuecher, F., Marx, A., Hess, G., Gschaidmeier, H., Gamm, H., Kirkpatrick, C. J., Huber, C., and Fischer, T. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood, 101: 2960-2962, 2003.
25. Mesters, R. M., Padro, T., Bieker, R., Steins, M., Kreuter, M., Goner, M., Kelsey, S., Scigalla, P., Fiedler, W., Buchner, T., and Berdel, W. E. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood, 98: 241-243, 2001.
26. Ueno, H., Honda, H., Nakamoto, T., Yamagata, T., Sasaki, K., Miyagawa, K., Mitani, K., Yazaki, Y., and Hirai, H. The phosphatidylinositol 3′ kinase pathway is required for the survival signal of leukocyte tyrosine kinase. Oncogene, 14: 3067-3072, 1997.
27. Reuss-Borst, M. A., Buhring, H. J., Schmidt, H., and Muller, C. A. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia (Baltimore), 8: 258-263, 1994.
28. Smith, F. O., Broudy, V. C., Zsebo, K. M., Lampkin, B. C., Buckley, C. V., Buckley, J. D., Opie, T., Woods, W. G., Hammond, G. D., and Bernstein, I. D. Cell surface expression of c-kit receptors by childhood acute myeloid leukemia blasts is not of prognostic value: a report from the Children's Cancer Group. Blood, 84: 847-852, 1994.
29. Lauria, F., Bagnara, G. P., Rondelli, D., Raspadori, D., Strippoli, P., Bonsi, L., Ventura, M. A., Montanaro, L. L., Bubola, G., Tura, S., et al. Cytofluorimetric and functional analysis of c-kit receptor in acute leukemia. Leuk. Lymphoma., 18: 451-455, 1995.
30. Gattei, V., Celetti, A., Cerrato, A., Degan, M., De Iuliis, A., Rossi, F. M., Chiappetta, G., Consales, C., Improta, S., Zagonel, V., Aldinucci, D., Agosti, V., Santoro, M., Vecchio, G., Pinto, A., and Grieco, M. Expression of the RET receptor tyrosine kinase and GDNFR-α in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. Blood, 89: 2925-2937, 1997.
31. Manie, S., Santoro, M., Fusco, A., and Billaud, M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet., 17: 580-589, 2001.
32. Santoro, M., Melillo, R. M., Carlomagno, F., Fusco, A., and Vecchio, G. Molecular mechanisms of RET activation in human cancer. Ann. N. Y. Acad. Sci., 963: 116-121, 2002.
33. Altanerova, V. Cancers connected with mutations in RET protooncogene. Neoplasma, 48: 325-331, 2001.
34. Visser, M., Hofstra, R. M., Stulp, R. P., Wu, Y., Buys, C. H., Willemze, R., and Landegent, J. E. Absence of mutations in the RET gene in acute myeloid leukemia. Ann. Hematol., 75: 87-90, 1997.
35. Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA, 95: 14863-14868, 1998.